Plain-English translation of NCT07292909 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers are testing whether empagliflozin, a medication typically used to treat diabetes, may have another powerful benefit: reducing inflammation after a heart stent is placed. While this medication has already been shown to help heart failure patients, doctors want to understand exactly how it works. This trial will measure whether taking the medication before a stent procedure can prevent the inflammatory response that normally occurs afterward.
This medication shows promise for heart health beyond just lowering blood sugar, but the exact reason is not yet understood. This study aims to test whether its anti-inflammatory properties—not just glucose control—explain why it helps heart patients, which could open new ways to protect people undergoing stent procedures.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take either the study medication or a placebo pill for 3 days before your scheduled stent procedure. Blood samples will be taken before your procedure and again 24 hours afterward to measure inflammation markers. The research team will compare these measurements between the two groups to see whether the medication reduces the inflammatory response that normally follows stent placement.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Lebanon